However, it has been identified as a potential prognostic biomarker in other cancers, for instance, in lung adenocarcinoma, where elevated CDK1 expression has been associated with more advanced stage, poor tumor differentiation, and the presence of TP53 mutations [55]. Here, CDK1 is linked to neoplasm.